The Global Cancer Immunotherapy Market was valued at USD 86 Bn in 2020 and is expected to reach USD 192.3 Bn by 2027, with a growing CAGR of 12.2% during the forecast period.
Global Cancer Immunotherapy Market Definition
Cancer immunotherapy is used to treat cancer patients by providing artificial stimulation to the immune system. This helps to enhance the immune system and gain the ability to fight the disease amongst the patients. In this therapy, an individual’s immune system is used to fight against cancer. Immunotherapy is expected to hold huge potential for curing cancers. Immunotherapy can also be used as standalone therapy along with other cancer treatments.
Global Cancer Immunotherapy Market Dynamics
The driving factors influencing the global cancer immunotherapy market include increasing incidences of cancer diseases such as lung cancer, blood cancer, and rising approval for innovative immunotherapy drug forms such as a vaccines and adjuvants. For instance, according to the clinical trial application no. NCT04267848, non-small-cell lung cancer hold the significant mortality every year across the world. After the successful incision of cancerous cells, platinum-based chemotherapy is expected to enhance the survival of patients till the recurrence of diseases. Adjuvant immunotherapy is expected to hold high efficacy and efficiency to improve the health of the patient which is expected to increase in demand for cancer immunotherapy during the forecast period. Moreover, ALCHEMIST, a clinical trial platform offered by the National Cancer Institute aimed to support and evaluate the chemotherapy plus pembrolizumab. This is supported by the pembrolizumab to the standard of care adjuvant platinum-based chemotherapy which is expected to pull the growth of adjuvant-based immunotherapy in the cancer immunotherapy demand in the market during the forecast period. Such ongoing research on the adjuvant chemotherapies and cancer vaccines are expected to propel the growth of the cancer immunotherapy demand during the forecast period. Furthermore, rising healthcare expenditure, government spending on R&D for cancer therapies, and growing number of clinical trials associated with cancer immunotherapy is expected to leverage the growth of the cancer immunotherapy demand in the ecosystem during the forecast period.
In addition, growing collaborations among pharmaceutical companies for the development and manufacturing of cancer immunotherapies are expected to boost the cancer immunotherapy demand in the market during the forecast period. For instance, in December 2021, Boehringer Ingelheim (Germany) collaborated with Enara Bio (Oxford, Oxfordshire, England) and signed licensing agreement to discover, design, and develop Novel Shared Antigens for Cancer Immunotherapy. This collaboration is expected to focus on gastrointestinal and lungs cancer and strengthen the position of Boehringer Ingelheim in the cancer vaccine and T-cells spaces. However, stringent regulatory policies for therapy approvals are expected to hinder the growth of cancer immunotherapy demand during the forecast period.
Global Cancer Immunotherapy Market Segmentation:
By End User
Company Profiles and Competitive Intelligence
The key players operating in the cancer immunotherapy market are:
Based on therapy, monoclonal antibodies segment is expected to hold largest market share during the forecast period due to the benefits offered by monoclonal antibodies in cancer treatment such as it helps to turn the immune system in the cancer
Based on therapy, cancer immunotherapy market is segmented into monoclonal antibodies, immunomodulators, cancer vaccines, and immune check point inhibitors. Monoclonal antibodies held largest market share in 2020 due to presence of large volume of cancer patients. This therapy is expected to dominate the market during forecast period due to rising demand for safe and effective cancer therapy which would trigger person’s own immunity system to fight against the cancer. Moreover, increasing usage of monoclonal antibodies for targeted therapy is expected to boost the cancer immunotherapy demand in the ecosystem during the forecast period. For instance, rituximab which binds with CD20 on B cells that tend to kill cells through immune system and helps to fight against cancer cells. Furthermore, increasing research activities related to the development of monoclonal antibodies such as Isatuximab (Multiple Myeloma, 2020) is expected to fuel the growth of the segment in the cancer immunotherapy market during the forecast period.
Based on applications, lung cancer segment is expected to contribute highest market growth during the forecast period due to increasing developments of immunotherapy procedures especially for non-small cell lung cancers
Based on applications, cancer immunotherapy market is broadly segmented into prostate cancer, lung cancer, skin cancer, and breast cancer. Lung cancer segment accounted for maximum market share in 2020 owing to increase in number of patients with lung cancer. According to WHO (World Health Organization) 2020, one-third of death across the world are due to consumption of Tobacco or alcohol or lack of physical activities which directly lead to the lung cancer. From out of 10 Mn deaths across the globe, ~2Mn deaths are reported with lung cancer. Such rising incidences of lung cancer across the globe is expected to fuel the growth of the cancer immunotherapy demand in the market during the forecast period. Furthermore, lung cancer segment is expected to observe high market growth during the forecast period due to rising consumption of smoking in the population.
Smoking is considered as primary risk factor and leading cause for lung cancer. In addition, growing number of FDA approvals for cancer immunotherapy is expected to pull the growth of cancer immunotherapy demand in the market during the forecast period. For instance, in March 2019, Roche (Switzerland) received US FDA approval for drug Atezolizumab (Tecentriq) which is used for the treatment of non-small cell lung cancer. Such therapy approvals are expected to trigger the growth of the cancer immunotherapy market during the forecast period.
Based on region, North America is expected to dominate the growth of the market during the forecast period due to increasing developments in healthcare infrastructure in this region
Based on region, North America is expected to hold largest market share during the forecast period due to rising number of cancers affected patients and increasing prevalence of cancer due to change in lifestyle. For instance, according to The Cancer Atlas, cancer is the leading cause of death in Canada. More than ~1.9 Mn are the new emerging cancer cases in North America. Such rising incidences of cancer cases are expected to leverage the growth of the cancer immunotherapy demand in the market during the forecast period. Furthermore, growing government initiatives in the terms of funds and awareness are expected to fuel the growth of the market during the forecast period.
The report also provides in-depth analysis of Cancer Immunotherapy market dynamics such as drivers, restraints, opportunities, and challenges
COVID-19 Impact on the Cancer Immunotherapy Market Analysis
Covid-19 has created havoc on the healthcare sector across the globe. Cancer immunotherapy market is negatively affected by the pandemic. Due to the burden of covid-19 cases on the hospitals and clinics, cancer affected patients which were not critical were kept on hold. Priority was given to the covid infected patients across the globe. Moreover, drug development process and clinical trials related to the cancer therapy were delayed due to continuous rising covid cases. However, the market is expected to flourish in coming years after normalization of the situation across the world. As covid-19 impacted the health of the patients with lung or gastrointestinal cancer, the market is expected to grow post-covid and anticipates the growth of the cancer immunotherapy during the forecast period.
The report also provides an in-depth analysis of key trends in cancer immunotherapy market
|1||Growing attention of researchers towards new cancer methodologies such as CAR T-cells, immune checkpoint inhibitors, and HPV vaccination||Positive|
|2||Rising interest of researchers towards functionalized nano system for targeted therapy||Positive|
The report also provides an in-depth analysis of recent news developments and investments
The unique insights provided by this report also includes the following:
Ask for free product review call with the author
Share your specific research requirements for a customized report
Request for due diligence and consumer centric studies
Request for study updates, segment specific and country level reports